For the second time this year, the FDA released a draft biosimilar guidance. The latest one describes what type of information a biosimilar sponsor should obtain about the structural/physicochemical and functional attributes of the reference biologic, how that information should be used to develop an analytical similarity assessment plan for the proposed biosimilar and what statistical approaches are recommended for evaluating analytical similarity.